Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06617312 · ClinicalTrials.gov registry record · Phase 2
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
A Phase 2 study of Smoking Cessation and Tobacco Use Disorder, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06617312 is a Phase 2 study of Smoking Cessation and Tobacco Use Disorder that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 64 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06617312, a Phase 2 study of Smoking Cessation and Tobacco Use Disorder, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will randomize 64 non-treatment seeking individuals who smoke cigarettes daily in a double-blind, placebo-controlled laboratory study testing the effects of cytisinicline on the neural substrates of cigarette cue reactivity.
Conditions Studied
Interventions
- DRUG Cytisinicline
- DRUG Placebo Oral Capsule
Study Locations (1)
California
- University of California Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06617312
The ClinicalTrials.gov registry entry for NCT06617312 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (86% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Cytisinicline is the first listed.
NCT06617312 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06617312 about?
NCT06617312 is a clinical study titled "Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity". This study will randomize 64 non-treatment seeking individuals who smoke cigarettes daily in a double-blind, placebo-controlled laboratory study testing the effects of cytisinicline on the neural substrates of cigarette cue reactivity.
What is the current status of trial NCT06617312?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2024-12-05. Estimated completion is 2026-12.
What conditions does trial NCT06617312 study?
This clinical trial studies the following conditions: Smoking Cessation, Tobacco Use Disorder.
What interventions are being tested in trial NCT06617312?
The interventions under investigation include: Cytisinicline (DRUG), Placebo Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT06617312?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06617312 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
RECRUITING · Phase 2
-
Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate
COMPLETED · Phase 2
-
Treating Smokers With Mental Illness
COMPLETED · Phase 2
-
Suvorexant to Reduce Symptoms of Nicotine Use
COMPLETED · Phase 2
-
Pharmacogenetics, Emotional Reactivity and Smoking
COMPLETED · Phase 2
-
Provoked Craving Relief Study by NRT
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.